公开(公告)号：US20240180966A1

公开(公告)日：2024-06-06

申请号：US18384390

申请日：2023-10-27

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yardena SAMUELS ,  Nir FRIEDMAN ,  Aviyah PERI ,  Erez GREENSTEIN ,  Michal ALON

IPC: A61K35/17 ,  A61K39/00

CPC classification number: A61K35/17 ,  A61K39/4611 ,  A61K2239/57

Abstract: A method of treating cancer in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a population of T cells, wherein an alpha chain of a TCR of at least 10% of the T cells of the population has a CDR3 amino acid sequence as set forth in SEQ ID NO: 6, and a beta chain of the CDR has a CDR3 amino acid sequence as set forth in SEQ ID NO: 7.

公开(公告)号：US20230242611A1

公开(公告)日：2023-08-03

申请号：US18107573

申请日：2023-02-09

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Rachel Lea EISENBACH ,  David BASSAN ,  Yosi GOZLAN ,  Esther TZEHOVAL ,  Nir FRIEDMAN ,  Erez GREENSTEIN

IPC: C07K14/725 ,  C12N9/78 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K14/7051 ,  C12Y305/04005 ,  C12N9/78 ,  A61K39/4632 ,  A61K39/4611 ,  A61K39/464486 ,  A61P35/00 ,  A61K39/4637 ,  A61K2239/25

Abstract: MAGE-A1 specific T cell receptors (TCRs) are provided. Accordingly, there is provided a TCR comprising a TCR α chain as set forth in SEQ ID NO: 1 having at least one mutation at an amino acid position selected from the group consisting of S189, G125, W55 and Y56; and/or a TCR β chain as set forth in SEQ ID NO: 2 having at least one mutation at an amino acid position selected from the group consisting of S32, S109 and T63, the TCR binds a MAGE-A1 peptide as set forth in SEQ ID NO: 25. Also provided are polynucleotides encoding the TCR and T cells expressing same and methods of use thereof.

公开(公告)号：US20220241331A1

公开(公告)日：2022-08-04

申请号：US17612279

申请日：2020-05-19

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yardena SAMUELS ,  Shelly KALAORA ,  Aviyah PERI ,  Nir FRIEDMAN ,  Shlomit REICH-ZELIGER ,  Erez GREENSTEIN

IPC: A61K35/17 ,  C07K14/47 ,  C07K14/725 ,  C07K14/82 ,  C12N5/0783

Abstract: A method of treating cancer in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of T cells expressing a T cell receptor (TCR) having a CDR3 amino acid sequence selected from the group consisting of 199-210.